M12.DE
Strong BuyFull HouseAI neutralM1 Kliniken AG · Healthcare · Germany · $417M
EUR 20.40 -1.9% · close 5 Oct · scored 7 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
M1 Kliniken commands a leading position in European aesthetic medicine with historically high capital efficiency and expansion momentum across beauty clinics. Nevertheless, recent trimming of forward earnings estimates suggests near-term friction in operating expense absorption. Without clear positive internal catalysts, the profile warrants patience.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT M1 KLINIKEN AG
Read
M1 Kliniken AG is the leading provider of aesthetic medicine and plastic surgery services in Germany, operating a highly standardized network of specialized clinics. The company's competitive moat is driven by its high-volume, low-price strategy, supported by centralized procurement and distribution of medical products like dermal fillers and botulinum toxin. It operates as a dominant, vertically integrated player in the rapidly growing private-pay aesthetic healthcare market.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 285.3M | 316.3M | 339.2M | 364.3M | 8.5% | 257.6M |
| EPS (EUR) | 0.24 | 0.54 | 0.85 | 1.19 | 70.5% | 1.08 |
| Shares | 18.3M | 19.1M | 18.8M | 18.8M | +2.5% | 18.6M |
| Debt | 13.7M | 10.8M | 10.4M | 7.1M | -19.5% | 5.9M |
| Equity | 95.5M | 113.3M | 106.1M | 119.9M | 7.9% | — |
| Op CF | 20.8M | 7.8M | 30.5M | 37.9M | 22.3% | 27.3M |
| Inv CF | -1.1M | -9.4M | -5.7M | -3.6M | — | — |
| Fin CF | -22.4M | -27.8M | -30.4M | -14.6M | — | — |
Swung more than 56% of stocks we rank over the past year (45% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of M12.DE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| M12.DE | M1 Kliniken AG(you) | $417M | 98 | Strong Buy |
| ILM1.DE | Medios AG | $290M | 74 | Buy |
| MED.DE | MEDICLIN Aktiengesellschaft | $295M | 97 | Strong Buy |
| SBS.DE | Stratec SE | $311M | 74 | Buy |
| LIK.DE | LIMES Schlosskliniken AG | $180M | 84 | Strong Buy |
| DRW8.DE | Drägerwerk AG & Co. KGaA | $1.9B | 99 | Strong Buy |
| RHK.DE | RHÖN-KLINIKUM Aktiengesellschaft | $1.1B | 83 | Strong Buy |
| EUZ.DE | Eckert & Ziegler SE | $881M | 79 | Buy |
| DMP.DE | Dermapharm Holding SE | $2.2B | 87 | Strong Buy |
| 1846.HK | EuroEyes International Eye Clinic Limited | $97M | 75 | Buy |
Peer medians: ROE 3.3% · P/E 19.2x · Gross margin 45.7%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.